What is the duration of action of Nicardia (Nifedipine) in a patient with hypertension or angina?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 4, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Duration of Action of Nicardia (Nifedipine)

Immediate-Release Formulation

The duration of action of immediate-release nifedipine (Nicardia) is 4-6 hours, requiring multiple daily doses (typically 3 times daily) to maintain therapeutic blood pressure control throughout 24 hours. 1

  • The antihypertensive response to each dose of immediate-release nifedipine lasts 8-12 hours in some patients, though this is variable and often insufficient for complete 24-hour coverage 2
  • Peak effect occurs at 60 minutes after oral administration, with onset of action at 30-45 minutes 1
  • Clinical studies demonstrate that for many patients, the duration of action is less than 12 hours, necessitating three-times-daily dosing to achieve 24-hour symptom relief 3

Important Clinical Context

  • The British Hypertension Society strongly recommends against using immediate-release nifedipine capsules due to safety concerns related to rapid blood pressure drops that can cause myocardial infarction or stroke 4
  • The American College of Cardiology advises that immediate-release formulations should only be used with concomitant beta-blockade due to increased risk of adverse cardiovascular events 4, 5

Extended-Release Formulation

Extended-release nifedipine (Nifedipine XL/Retard) maintains therapeutic blood levels for approximately 24 hours, allowing once-daily dosing. 4

  • The elimination half-life of extended-release nifedipine is approximately 7 hours, compared to 2 hours for immediate-release formulations 6
  • Plasma concentrations peak at 2.5-5 hours with a second small peak at 6-12 hours post-dose, providing sustained drug levels 6
  • The extended-release formulation provides more consistent plasma concentrations and reduces fluctuations compared to immediate-release given three times daily 6

Dosing Recommendations

  • For hypertension and angina: 30-180 mg once daily of extended-release formulation 4, 5
  • The American Heart Association recommends the extended-release formulation as preferred due to better safety profile and improved adherence 4

Critical Clinical Pearls

  • The variable first-pass metabolism of nifedipine leads to substantial inter-individual differences in plasma concentrations, which explains why duration of action varies between patients 3
  • When switching between formulations, be aware that 120 mg of immediate-release liquid divided throughout the day approximates the steady blood levels of a single 120 mg XL tablet, but the extended-release is strongly preferred for safety 4
  • Plasma nifedipine concentration is closely related to efficacy, though the absolute concentration required varies between individuals 3

References

4
Guideline

Nifedipine Dosing Guidelines for Hypertension and Angina

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

5
Guideline

Nifedipine Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What is the recommended dosage of Nifedipine for managing hypertension or angina?
What is the onset of action of nifedipine?
What is the half-life of nifedipine (calcium channel blocker) in a patient with hypertension?
What is the time of action of nifedipine (calcium channel blocker)?
What is the recommended dosage and administration of nifedipine (calcium channel blocker) for managing hypertension and angina?
What is the duration of action of Nicardia R (nicardipine) in a patient with severe hypertension?
What is the recommended subcutaneous (subcutaneous) heparin (heparin) regimen for bridging to oral anticoagulation in patients with atrial fibrillation (AF) and impaired renal function (renal impairment)?
What is the best approach for a patient with a body mass index (BMI) of 31, hypertension (HTN), and a family history of myocardial infarction (MI), who is requesting Glucagon-like peptide-1 (GLP-1) receptor agonists, such as liraglutide (Victoza) or semaglutide (Ozempic), for weight loss?
What is the preferred initial anticoagulant treatment between Low Molecular Weight Heparin (LMWH) and fondaparinux for a patient with acute deep vein thrombosis (DVT)?
What drops are recommended for a patient with blepharitis?
What is the best treatment approach for a 60-year-old woman with a cT2 (22mm) N0 G3 (ER negative, PR negative, HER2 positive) right breast carcinoma, who is undergoing primary therapy with chemotherapy (PTCP) and has developed neutropenia?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question